Advanced Practice Provider Core Curriculum: Painful Bladder Syndrome and Interstitial Cystitis (2017)

Member only benefit! Results of a recent survey sent to US based practicing urologists show that there has been an increase in the number of advanced practice providers (APPs) actively providing front-line urologic care. Based on these findings, it was determined that the AUA develop a modular curriculum to be used in advancing the standard of urologic education for APP’s. This educational curriculum, developed in partnership with the Cleveland Clinic, is comprised of online videos targeted towards the most common reasons patients seek non-operative urologic care. This module provides APPs with the framework for managing patients with painful bladder syndrome and interstitial cystitis.

AUA would like to acknowledge the following individuals from the Cleveland Clinic for their contributions in assembling and editing this case:

  • Hadley Wood, MD, FACS
  • Dana Longo, APRN, MPH
  • Nikki Williams, Project Manager

Target Audience

  • Physician Assistants
  • Advanced Practice Nurses
  • Med. Tech/Assistant
  • Medical Student
  • Nurse

Learning Objectives

After completion of this activity, participants will be able to:

  1. Discuss proposed theories of painful bladder syndrome (PBS) pathophysiology
  2. Describe PBS diagnostic process, including using appropriate terminology and urinary diaries
  3. Explain the role of diet on PBS symptoms
  4. Interpret cystoscopy, cytology and bladder biopsy findings for PBS patients
  5. Describe the risks, benefits, and alternatives for a variety of interventions
Course summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Non-Physician Participation
Course opens: 
02/17/2017
Course expires: 
02/17/2020
Rating: 
0

Faculty Disclosures: 

Jessica Lloyd, MD: Nothing to disclose
Juan Guzman-Negron, MD: Nothing to diclose
Sandip Vasavada, MD: NDI Medical LLC: Investment Interest; Allergan: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Medtronic: Meeting Participant or Lecturer; Axonics: Consultant or Advisor
Hadley Wood, MD: Nothing to disclose

Planner Disclosures:

Education Council
Timothy Charles Brand, MD: Nothing to disclose
Anthony A. Caldamone MD: Nothing to disclose
Peter Robert Carroll, MD, MPH: NIH: Scientific Study or Trial; Department of Defense: Scientific Study or Trial; Myriad Genetics: Scientific Study or Trial; AUA Update: Leadership Position; Genomic Health: Scientific Study or Trial
Sam S. Chang, MD: Astellas: Consultant or Advisor; NIH: Scientific Study or Trial; GLG: Consultant or Advisor; Janssen: Consultant or Advisor
Matthew S. Christman MD: Nothing to disclose
Jody Donaldson (AUA Staff): Nothing to disclose
Shelby Englert (AUA Staff): Nothing to disclose
Matthew Thomas Gettman, MD: Nothing to disclose
Inderbir Singh Gill ,MD, M.Ch.: Nothing to disclose
Howard B. Goldman, MD: Allergan: Consultant or Advisor; Astellas: Consultant or Advisor; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Cook: Scientific Study or Trial; Nuvectra: Consultant or Advisor
William C. Huang, MD: Photocure: Scientific Study or Trial
William C. Hulbert Jr. MD: Nothing to disclose
Brant Inman, MD, MS, FRCSC: Dendreon: Scientific Study or Trial; Abbott Laboratories: Scientific Study or Trial; Genentech Inc: Scientific Study or Trial; Combat Medical: Consultant or Advisor; FKD Therapies: Scientific Study or Trial; AstraZeneca: Consultant or Advisorl; Taris Biomedical: Consultant or Advisor
Mark L. Jordan MD,FACS: Nothing to disclose
Hari K. Koul, MSC,PHD: Novartis Pharmaceuticals: Consultant or Advisor; Urologic Research: Leadership Position; PLOS one: Leadership Position; OMICS group: Leadership Position; Open Access Publishing: Leadership Position, Health Publishing
Martin A. Koyle MD: Nothing to disclose
John Stephen Lam MD: Nothing to disclose
Yair Lotan ,MD: abbott: Scientific Study or Trial; Cepheid: Consultant or Advisor, Scientific Study or Trial; Pacific Edge: Scientific Study or Trial; FKD: Scientific Study or Trial; MDxHealth: Consultant or Advisor, Scientific Study or Trial; biocancell: Scientific Study or Trial; Genomic Health: Scientific Study or Trial; GenomeDx Biosciences Inc: Scientific Study or Trial; photocure: Consultant or Advisor, Scientific Study or Trial
Nicole Lara Miller ,MD: Lumenis: Meeting Participant or Lecturer; Boston Scientific Corporation: Consultant or Advisor, Meeting Participant or Lecturer
Manoj Monga, MD: Fortec: Other; endourology society: Leadership Position
Victor William Nitti MD: Astellas: Health Publishing, Scientific Study or Trial; Allergan: Health Publishing, Scientific Study or Trial; Serenity Pharmeuticals: Investment Interest; Cook Myosite: Scientific Study or Trial
Christopher Porter, MD: Nothing to disclose
Gail S. Prins PhD: Nothing to disclose
Ganesh V. Raj MD, PhD: Ptares: Owner, Product Development; C-diagnostics corp: Consultant or Advisor, Investment Interest; amgen: Meeting Participant or Lecturer; Johnson and Johnson: Consultant or Advisor, Owner, Product Development; Astellas: Meeting Participant or Lecturer; ASTELLAS: Consultant or Advisor, Meeting Participant or Lecturer; Janssen: Owner, Product Development; BAYER: Consultant or Advisor, Meeting Participant or Lecturer; SANOFI: Consultant or Advisor, Meeting Participant or Lecturer; Gaudium: Leadership Position, Investment Interest, Owner, Product Development; Medivation: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
Jay D. Raman, MD: American Kidney Stone Management: Investment Interest
Lee Richstone, MD: Nothing to disclose
Heather Schultz, NP: SUNA: Meeting Participant or Lecturer
Karl-Dietrich Sievert ,MD, PhD: AMS: Meeting Participant or Lecturer; Medtronics: Meeting Participant or Lecturer, Scientific Study or Trial; Allergen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Neotract: Meeting Participant or Lecturer
Joseph A. Smith Jr.,MD: Nothing to disclose
Ryan Patrick Terlecki, MD, FACS: American Medical Systems: Consultant or Advisor, Other; Allergan: Scientific Study or Trial; GenomeDx: Consultant or Advisor

APN/PA Education Committee
Timothy Charles Brand, MD: Nothing to disclose
Anne E. Calvaresi NP,CRNP: Nothing to disclose
Jody Donaldson (AUA Staff): Nothing to disclose
Todd James Doran, ED.D, PA-C, DFAAPA: Physician Assistant Education Association: Other
Shelby Englert (AUA Staff): Nothing to disclose
James R. Kovarik III, PA-C: Nothing to disclose
Thomas Patrick McBride ,PA-C: Nothing to disclose
Kenneth Mitchell, MPAS, PA-C: Nothing to disclose
Karen A. Poe NP: Nothing to disclose
Jody A. Purifoy, DNP, APRN, CNP: Nothing to disclose
Ashleigh Renitsky, PA-C: Nothing to disclose
Thomas Alan Rozanski ,MD: Nothing to disclose
Rochell L. Sasse ,MSN, RN, ACNP: Metronic: Consultant or Advisor; no more: Other
Heather Schultz, NP: SUNA: Meeting Participant or Lecturer
Daniel Thomas Vetrosky, PA-C: Nothing to disclose: 
Gwendolyn Brooke Zilinskas ,PA-C: Nothing to disclose
Tricia Zubert, NP: Nothing to disclose  
 

Method of Participation

Learners will participate in this online educational activity by taking an online pre- and post-test and viewing the online video. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 0.75 hour

Release Date: February, 2017
Expiration Date: February, 2020

Accreditation

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices

It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

 

Available Credit

  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Non-Physician Participation
Please login or register to take this course.